CI vs IBRX · P/E 2.4, rev $274.90B vs rev $113.3M
Cigna Corp (CI) versus Immunitybio Inc (IBRX) — a side-by-side from cached financials, not a winner call.
Cigna Corp (CI) is a healthcare plans company listed on US.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Latest reported CI revenue for 2025-12-31 was $274.90B. Net income was $5.96B. Revenue was up 11.2% from 2024-12-31 to 2025-12-31. CI currently screens at market cap $71.62B and trailing P/E 2.4.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
CI currently screens at market cap $71.62B and trailing P/E 2.4. IBRX currently screens at market cap $7.88B.
Not investment advice. Open the CI and IBRX stock pages for the full models.
Not investment advice.